Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment

Saudi Journal of Biological Sciences

Volumn 22, Issue 1, 2015, Pages 90-101

  Shaikh, Sibhghatulla ^a   Fatima, Jamale ^a   Shakil, Shazi ^a   Rizvi, Syed Mohd Danish ^a   Kamal, Mohammad Amjad ^b,c  

^a INTEGRAL UNIVERSITY   (India)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c Enzymoics   (Australia)

Author keywords

Amino acid; Antibiotics; Antimicrobial agents; Carbapenems; Enterobacteriaceae; Extended spectrum lactamase

Indexed keywords

ENTEROBACTERIACEAE;

EID: 85027945284     PISSN: 1319562X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sjbs.2014.08.002     Document Type: Article

References (112)

1. Abhijit A., Sunita N., Maria K. Study of urinary isolates with reference to extended spectrum beta lactamases detection and antibiogram. J. Evol. Med. Dent. Sci. 2013, 2(9):1049-1055.
2. Aktas Z., Kayacan C.B., Schneider I., Can B., Midilli K., Bauernfeind A. Carbapenem hydrolyzing oxacillinase, OXA-48, persists in Klebsiella pneumoniae in Istanbul, Turkey. Chemotherapy 2008, 54(2):101-106.
3. Al Benwan K., Al Sweih N., Rotimi V.O. Etiology and antibiotic susceptibility patterns of community and hospital acquired urinary tract infections in a general hospital in Kuwait. Med. Princ. Pract. 2010, 19(6):440-446.
4. Al-Agamy M.H.Mohamed, El-Din Ashour M.S., Wiegand I. First description of CTXM beta-lactamase-producing clinical Escherichia coli isolates from Egypt. Int. J. Antimicrob. Agents 2006, 27(6):545-548.
5. Alekshun M.N., Levy S.B. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007, 128:1037-1050.
6. Alsterlund R., Carlsson B., Gezelius L., Haeggman S., Olsson-Liljequist B. Multi resistant CTX-M-15 ESBL-producing Escherichia coli in southern Sweden: description of an outbreak. Scand. J. Infect. Dis. 2009, 41(6-7):410-415.
7. Ambler R.P. The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 1980, 289:321-331.
8. Barthelemy M., Péduzzi J., Labia R. Distinction entre les structures primaires des beta-lactamases TEM-1 et TEM-2. Ann. Inst. Pasteur. Microbiol. 1985, 136(3):311-321.
9. CTX-M genes in clinical Salmonella isolates recovered from humans in England and Wales from 1992 to 2003. Antimicrob. Agents Chemother. 2005, 49(4):1319-1322.
10. Bauernfeind A., Stemplinger I., Jungwirth R., Ernst S., Casellas J.M. Sequences of β-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other β-lactamases. Antimicrob. Agents Chemother. 1996, 40:509-513.
11. Benton B., Breukink E., Visscher I., Debabov D., Lunde C., Janc J., Mammen M., Humphrey P. Telavancin inhibits peptidoglycan biosynthesis through preferential targeting of transglycosylation: evidence for a multivalent interaction between telavancin and lipid II. Int. J. Antimicrob. Agents 2007, 29:51-52.
12. Bhusal Y., Mihu C.N., Tarrand J.J., Rolston K.V. Incidence of fluoroquinolone-resistant and extended-spectrum beta-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy 2011, 57(4):335-338. (Biol. Sci. 289, 321-331).
13. Birkett C.I., Ludlam H.A., Woodford N., Brown D.F., Brown N.M., Roberts M.T., Milner N., Curran M.D. Real-time TaqMan PCR for rapid detection and typing of genes encoding CTX-M extended-spectrum β-lactamases. J. Med. Microbiol. 2007, 56:52-55.
14. Blanchard A. Bacterial acetyltransferase capable of regioselective N-acetylation of antibiotics and histones. Chem. Biol. 2004, 11:565-573.
15. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob. Agents Chemother. 2004, 48(1):1-14.
16. Bradford P.A. Extended spectrum beta-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Clin. Microbiol. Rev. 2001, 14:933-951.
17. Bradford P.A., Yang Y., Sahm D., Grope I., Gardovska D., Storch G. CTX-M-5, a novel cefotaxime-hydrolyzing b-lactamase from an outbreak of Salmonella typhimurium in Latvia. Antimicrob. Agents Chemother. 1998, 42:1890-1894.
18. Brisson-Noel A., Delrieu P., Samain D., Courvalin P. Inactivation of lincosaminide antibiotics in Staphylococcus: identification of lincosaminide O-nucleotidyltransferases and comparison of the corresponding resistance genes. J. Biol. Chem. 1988, 263:15880-15887.
19. Bush K., Fisher J.F. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu. Rev. Microbiol. 2011, 65:455-478.
20. Bush K., Jacoby G.A. An updated functional classification of-lactamases. Antimicrob. Agents Chemother. 2010, 54(3):969-976.
21. Bush, K., Jacoby, G.A., Beta-lactamase classification and amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant enzymes. Available from: (accessed 27.10.2012). http://www.lahey.org/Studies/.
22. Bush K., Jacoby G.A., Medeiros A.A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 1995, 39:1211-1233.
23. Canton R., Novais A., Valverde A., Machado E., Peixe L., Baquero F., Coque T.M. Prevalence and spread of extended-spectrum beta-lactamase producing Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 2008, 1:144-153.
24. Carattoli A. Animal reservoirs for extended spectrum beta-lactamase producers. Clin. Microbiol. Infect. 2008, 1:117-123.
25. Cars O., Molstad S., Melander A. Variation in antibiotic use in the European Union. Lancet 2001, 357(9271):1851-1883.
26. Coque T.M., Baquero F., Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro. Surveill. 2008, 13(47):1-11.
27. Coque T.M., Novais A., Carattoli A., Poirel L., Pitout J., Peixe L., Baquero F., Cantón R., Nordmann P. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg. Infect. Dis. 2008, 14(2):195-200.
28. Datta N., Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 1965, 208:239-241.
29. Du Bois S.K., Marriott M.S., Amyes S.G. TEM- and SHV-derived extended-spectrum beta-lactamases: relationship between selection, structure and function. J. Antimicrob. Chemother. 1995, 35:7-22.
30. Ensor V.M., Shahid M., Evans J.T., Hawkey P.M. Occurrence, prevalence and genetic environment of CTX-M beta-lactamases in Enterobacteriaceae from Indian hospitals. J. Antimicrob. Chemother. 2006, 58(6):1260-1263.
31. Ensor V.M., Livermore D.M., Hawkey P.M. A novel reverse-line hybridization assay for identifying genotypes of CTX-M-type extended-spectrum β-lactamases. J. Antimicrob. Chemother. 2007, 59:387-395.
32. European Antimicrobial Resistance Surveillance System, 2011. (accessed 16-09-2011). http://www.rivm.nl/earss/database/.
33. Fatemeh A., Emran A., Elnaz K., Mohammad J.G.S., Mahboubeh N. The frequency of extended spectrum beta lactamase (ESBL) in Escherichia coli and Klebsiella pneumonia: a report from Mashhad, Iran. J. Med. Bacteriol. 2012, 1(3):12-19.
34. Fernandez V.M., Munoz B.J.L., Garcia G.M.I., Garcia R.J.A. Salmonella enterica serovar Enteritidis producing a TEM-52 beta-lactamase: first report in Spain. Diagn. Microbiol. Infect. Dis. 2006, 55(3):245-256.
35. Fisher J.F., Mobashery S. Enzymology of Bacterial Resistance. Comprehensive Natural Products II. Enzymes and Enzyme Mechanisms 2010, vol. 8:443-487. Elsevier.
36. Gazouli M., Tzelepi E., Markogiannakis A., Legakis N.J., Tzouvelekis L.S. Two novel plasmid-mediated cefotaxime hydrolyzing b-lactamases (CTX-M-5 and CTX-M-6) from Salmonella typhimurium. FEMS. Microbiol. Lett. 1998, 165:289-293.
37. Gupta V. An update on newer β-lactamases. Indian J. Med. Res. 2007, 126(5):417-427.
38. Hawkey P.M. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin. Microbiol. Infect. 2008, 14(1):159-165.
39. Herindrainy P., Randrianirina F., Ratovoson R., Ratsima H.E., Buisson Y., Genel N., Decré D., Arlet G., Talarmin A., Richard V. Rectal carriage of extended-spectrum beta-lactamase-producing gram negative bacilli in community settings in Madagascar. PLoS ONE 2011, 6(7):e22738.
40. Hirakata Y., Matsuda J., Miyazaki Y., Kamihira S., Kawakami S., Miyazawa Y., Ono Y., Nakazaki N., Hirata Y., Inoue M., Turnidge J.D., Bell J.M., Jones R.N., Kohno S. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn. Microbiol. Infect. Dis. 2005, 52(4):323-329.
41. Ho P.L., Yip K.S., Chow K.H., Lo J.Y., Que T.L., Yuen K.Y. Antimicrobial resistance among uropathogens that cause acute uncomplicated cystitis in women in Hong Kong: a prospective multicenter study in 2006 to 2008. Diagn. Microbiol. Infect. Dis. 2010, 66:87-93.
42. Humeniuk C., Arlet G., Gautier V., Grimont P., Labia R., Philippon A. β-lactamases of Kluyvera ascorbata, probable progenitors of some plasmid-encoded CTX-M types. Antimicrob. Agents Chemother. 2002, 46:3045-3049.
43. Ibuka A., Taguchi A., Ishiguro M., Fushinobu S., Ishii Y., Kamitori S., Okuyama K., Yamaguchi K., Konno M., Matsuzawa H. Crystal structure of the E166A mutant of extended-spectrum beta-lactamase Toho-1 at 1.8 A° resolution. J. Mol. Biol. 1999, 285:2079-2087.
44. Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae-EUCAST and CLSI breakpoints. Clin. Microbiol. Infect. 2008, 14:169-174.
45. Khanfar H.S., Bindayna K.M., Senok A.C., Botta G.A. Extended spectrum beta lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. J. Infect. Dev. Ctries. 2009, 3(4):295-299.
46. Knothe H., Shah P., Krcmery V., Antal M., Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983, 11:315-317.
47. Kritu P., Prakash G., Shiba K.R., Reena K.M., RAM N.S., Ganesh R. Antibiogram typing of gram negative isolates in different clinical samples of a tertiary hospital. Asian J. Pharm. Clin. Res. 2013, 6(1):153-156.
48. Kumarasamy K.K., Toleman M.A., Walsh T.R., Bagaria J., Butt F., Balakrishnan R., Chaudhary U., Doumith M., Giske C.G., Irfan S., Krishnan P., Kumar A.V., Maharjan S., Mushtaq S., Noorie T., Paterson D.L., Pearson A., Perry C., Pike R., Rao B., Ray U., Sarma J.B., Sharma M., Sheridan E., Thirunarayan M.A., Turton J., Upadhyay S., Warner M., Welfare W., Livermore D.M., Woodford N. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 2010, 10(9):597-602.
49. Leach K.L., Swaney S.M., Colca J.R., McDonald W.G., Blinn J.R., Thomasco L.M., Gadwood R.C., Shinabarger D., Xiong L., Mankin A.S. The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. Mol. Cell. 2007, 26:393-402.
50. Livermore D.M. Beta-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 1995, 8:557-584.
51. Ma L., Ishii Y., Ishiguro M., Matsuzawa H., Yamaguchi K. Cloning and sequencing of the gene encoding Toho-2, a class A β-lactamase preferentially inhibited by tazobactam. Antimicrob. Agents Chemother. 1998, 42:1181-1186.
52. Majda Q., Najma A., Summyia B. Evaluation of extended spectrum beta-lactamase mediated resistance in Escherichia coli and Klebsiella in urinary tract infection at a tertiary care hospital. Biomedica 2013, 29:78-81.
53. Mathai D., Rhomberg P.R., Biedenbach D.J., Jones R.N. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn. Microbiol. Infect. Dis. 2002, 44(4):367-377.
54. Matsuoka M., Sasaki T. Inactivation of macrolides by producers and pathogens. Curr. Drug Targets Infect. Disord. 2004, 4:217-240.
55. Meeta S., Sati P., Preeti S. Prevalence and antibiogram of extended spectrum β-lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp. J. Clin. Diag. Res. 2013, 7(10):2168-2172.
56. Moubareck C., Daoud Z., Hakime N.I., Hamze M., Mangeney N., Matta H., Mokhbat J.E., Rohban R., Sarkis D.K., Doucet-Populaire F. Countrywide spread of community- and hospital acquired extended-spectrum beta-lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon. J. Clin. Microbiol. 2005, 43(7):3309-3313.
57. Mshana S.E., Kamugisha E., Mirambo M., Chakraborty T., Lyamuya E.F. Prevalence of multi resistant gram-negative organisms in a tertiary hospital in Mwanza, Tanzania. BMC Res. Notes. 2009, 26(2):49. 10.1186/1756-0500-2-49.
58. Naas T., Oxacelay C., Nordmann P. Identification of CTX-M-type extended spectrum-β-lactamase genes using real-time PCR and pyrosequencing. Antimicrob. Agents Chemother. 2007, 51:223-230.
59. Naas T., Poirel L., Nordmann P. Minor extended-spectrum β-lactamases. Clin. Microbiol. Infect. 2008, 14(1):42-52.
60. Nasa P., Juneja D., Singh O., Dang R., Singh A. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome. Eur. J. Intern. Med. 2012, 23(2):192-195.
61. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 12th informational supplement. M100-S12. Wayne, P.A., National Committee for Clinical Laboratory Standards, 2002.
62. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003, 289:885-888.
63. Nordmann P., Poirel L., Walsh T.R., Livermore D.M. The emerging NDM carbapenemases. Trends Microbiol. 2011, 19:588-595.
64. Olson A.B., Silverman M., Boyd D.A., McGeer A., Willey B.M., Pong-Porter V., Daneman Mulvey M.R. Identification of a progenitor of the CTX-M-9 group of extended-spectrum β-lactamases from Kluyvera georgiana isolated in Guyana. Antimicrob. Agents Chemother. 2005, 49:2112-2115.
65. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 2005, 18:657-686.
66. Paterson D.L., Ko W.C., Von G.A., Casellas J.M., Mulazimoglu L., Klugman K.P., Bonomo R.A., Rice L.B., McCormack J.G., Yu V.L. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 2001, 39:2206-2212.
67. Perez F., Endimiani A., Hujer K.M., Bonomo R.A. The continuing challenge of ESBLs. Curr. Opin. Pharmacol. 2007, 7:459-469.
68. Perilli M., Segatore B., Mugnaioli C., Celenza G., Rossolini G.M., Stefani S., Luzzaro F., Pini B., Amicosante G. Persistence of TEM-52/TEM-92 and SHV-12 extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Italy. Microb. Drug Resist. 2011, 17(4):521-524.
69. Perry J.D., Naqvi S.H., Mirza I.A., Alizai S.A., Hussain A., Ghirardi S., Orenga S., Wilkinson K., Woodford N., Zhang J., Livermore D.M., Abbasi S.A., Raza M.W. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J. Antimicrob. Chemother. 2011, 66(10):2288-2294.
70. Petroni A., Corso A., Melano R., Cacace M.L., Bru A.M., Rossi A., Galas M. Plasmidic extended-spectrum beta-lactamases in Vibrio cholerae O1 El Tor isolates in Argentina. Antimicrob. Agents Chemother. 2002, 46:1462-1468.
71. Philippon L.N., Naas T., Bouthors A.T., Barakett V., Nordmann P. OXA-18, a class D clavulanic acid-inhibited extended-spectrum beta lactamase from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1997, 41:2188-2195.
72. Pitout J.D., Laupland K.B. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public health concern. The Lan. Infect. Dis. 2008, 8(3):159-166.
73. Pitout J.D., Hossain A., Hanson N.D. Phenotypic and molecular detection of CTX-M-β-lactamases produced by Escherichia coli and Klebsiella spp. J. Clin. Microbiol. 2004, 42:5715-5721.
74. Pitout J.D., Gregson D.B., Church D.L., Elsayed S., Laupland K.B. Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health region. J. Clin. Microbiol. 2005, 43(6):2844-2849.
75. Pitout J.D., Hamilton N., Church D.L., Nordmann P., Poirel L. Development and clinical validation of a molecular diagnostic assay to detect CTX-M-type β-lactamases in Enterobacteriaceae. Clin. Microbiol. Infect. 2007, 13:291-297.
76. Poirel L., Le Thomas I., Naas T., Karim A., Nordmann P. Biochemical sequence analyses of GES-1, a novel class A extended-spectrum β-lactamase, and the class 1 integron in 52 from Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2000, 44:622-632.
77. Poirel L., Girlich D., Naas T., Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob. Agents Chemother. 2001, 45:447-453.
78. Poirel L., Kampfer P., Nordmann P. Chromosome-encoded Ambler class A β-lactamase of Kluyvera georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 2002, 46:4038-4040.
79. Rice L.B., Willey S.H., Papanicolaou G.A., Medeiros A.A., Eliopoulos G.M., Moellering R.C.J., Jacoby G.A. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob. Agents Chemother. 1990, 34(11):2193-2199.
80. Rossi F., Garcia P., Ronzon B., Curcio D., Dowzicky M.J. Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz. J. Infect. Dis. 2008, 12(5):405-415.
81. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 2003, 51:1109-1117.
82. Rupinder B., Geeta W., Shikha J. Prevalence of extended spectrum β-lactamases in multidrug resistant strains of gram negative Bacilli. J. Acad. Indus. Res. 2013, 1(9):558-560.
83. Ruth A.A., Damian C.O., Romanus I.I., Charles O.E. Antimicrobial resistance status and prevalence rates of extended spectrum beta-lactamase producers isolated from a mixed human population. Bosnian J. Basic Med. Sci. 2011, 11(2):91-96.
84. Sanchez G.V., Master R.N., Karlowsky J.A., Bordon J.M. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob. Agents Chemother. 2012, 56(4):2181-2183.
85. Sankar S., Narayanan H., Kuppanan S., Nandagopal B. Frequency of extended spectrum beta-lactamase (ESBL)-producing Gram-negative bacilli in a 200-bed multi-specialty hospital in Vellore district, Tamil Nadu, India. Infection 2012, 40(4):425-429.
86. Schwarz S., Kehrenberg C., Doublet B., Cloeckaert A. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol. Rev. 2004, 28:519-542.
87. Shakti R., Debasmita D., Mahesh C., Sahu R., Padhy N. Surveillance of ESBL producing multidrug resistant Escherichia coli in a teaching hospital in India. Asian Pac. J. Trop. Dis. 2014, 4(2):140-149.
88. Siegel, J.D., Rhinehart, E., Jackson, M., Chiarello, L., 2006. Health Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings, http://www.cdc.gov/%20ncidod/dhqp/pdf/ar/MDROGuideline2006.pdf.
89. Sirot D., Sirot J., Labia R., Morand A., Courvalin P., Darfeuille-Michaud A., Perroux R., Cluzel R. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel beta lactamase. J. Antimicrob. Chemother. 1987, 20(3):323-334.
90. Soughakoff W., Goussard S., Courvalin P. TEM-3 beta-lactamases which hydrolyzes broad-spectrum cephalosporins is derived from the TEM-2 penicillinases by two amino acid substitutions. FEMS Microbiol. Lett. 1988, 56:343-348.
91. Spanu T., Sanguinetti M., Tumbarello M., D'Inzeo T., Fiori B., Posteraro B., Santangelo R., Cauda R., Fadda G. Evaluation of the new VITEK 2 extended-spectrum β-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates. J. Clin. Microbiol. 2006, 44:3257-3262.
92. Spratt B.G. Resistance to antibiotics mediated by target alterations. Science 1994, 264:388-393.
93. Steward C.D., Wallace D., Hubert S.K., Lawton R., Fridkin S.K., Gaynes R.P., McGowan J.E., Tenover F.C. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories. Diag. Microbiol. Infect. Dis. 2000, 38(1):59-67.
94. Straus S.K., Hancock R.E.W. Mode of action of the new antibiotic for gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptide. Biochim. Biophys. Acta 2006, 1758:1215-1223.
95. Strohl W.R. Biotech Antibiotics 1997, Marcel Dekker Inc., New York, USA.
96. Swedish Institute for Infectious Disease Control, 2012. Available from: (accessed 16-04-12). http://www.smi.se/in-english/statistics/extended-spectrum-beta-lactamaseesbl/.
97. Tande D., Jallot N., Bougoudogo F., Montagnon T., Gouriou S., Sizun J. Extended spectrum beta-lactamase-producing Enterobacteriaceae in a Malian orphanage. Emerg. Infect. Dis. 2009, 15(3):472-474.
98. Tawfik A.F., Alswailem A.M., Shibl A.M., Al-Agamy M.H. Prevalence and genetic characteristics of TEM, SHV, and CTX-M in clinical Klebsiella pneumoniae isolates from Saudi Arabia. Microb. Drug Resist. 2011, 17(3):383-388.
99. Thakur S., Pokhrel N., Sharma M. Prevalence of multidrug resistant enterobacteriaceae and extended spectrum β lactamase producing Escherichia coli in urinary tract infection. R.J.P.B.C.S. 2013, 4(2):1615-1624.
100. Tzouvelekis L.S., Bonomo R.A. SHV-type β-lactamases. Curr. Pharm. Des. 1999, 5:847-864.
101. Tzouvelekis L.S., Tzelepi E., Tassios P.T., Legakis N.J. CTX-M type beta-lactamases: an emerging group of extended-spectrum enzymes. Int. J. Antimicrob. Agents 2000, 14:137-143.
102. UK Health Protection Agency. Laboratory detection and reporting of bacteria with extended spectrum β-lactamases. QSOP 51. (accessed 17.01.2008). http://%20www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop51.%20pdf.
103. Vahaboglu H., Ozturk R., Aygun G., Coskunkan F., Yaman A., Kaygusuz A., Leblebicioglu H., Balik I., Aydin K., Otkun M. Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob. Agents Chemother. 1997, 41:2265-2269.
104. Vahaboglu H., Coskunkan F., Tansel O., Ozturk R., Sahin N., Koksal I., Kocazeybek B., Tatman-Otkun M., Leblebicioglu H., Ozinel M.A., Akalin H., Kocagoz S., Korten V. Clinical importance of extended-spectrum beta-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J. Med. Microbiol. 2001, 50:642-645.
105. Walsh C. Antibiotics: actions, origins, resistance 2003, ASM Press, Washington, DC.
106. Weldhagen G.F., Poirel L., Nordmann P. Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob. Agents Chemother. 2003, 47:2385-2392.
107. Wiegand I., Geiss H.K., Mack D., Sturenburg E., Seifert H. Detection of extended-spectrum β-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. J. Clin. Microbiol. 2007, 45:1167-1174.
108. Winokur P.L., Canton R., Casellas J.M., Legakis N. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin. Infect. Dis. 2001, 32:94-103.
109. Wolter D.J., Hanson N.D., Lister P.D. Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol. Lett. 2004, 236:137-143.
110. Woodford N., Fagan E.J., Ellington M.J. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum β-lactamases. J. Antimicrob. Chemother. 2006, 57:154-165.
111. Woodford N., Turton J.F., Livermore D.M. Multi resistant gram negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol. Rev. 2011, 35:736-755.
112. Yang W., Moore I.F., Koteva K.P., Bareich D.C., Hughes D.W., Wright G.D. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J. Biol. Chem. 2004, 279:52346-52352.